Journal of Neuro-Oncology

, Volume 11, Issue 1, pp 1–15 | Cite as

Medulloblastoma: tumor biological and clinical perspectives

  • Henry S. Friedman
  • W. fnJerry Oakes
  • Sandra H. Bigner
  • Carol J. Wikstrand
  • Darell D. Bigner

Summary

Medulloblastoma is the most common central nervous system malignancy of childhood, with approximately 350 new cases seen in the United States each year. Although the low incidence of this tumor, compared with adult neoplasms such as breast or colon carcinoma, has limited laboratory and clinical research, recent studies have greatly enhanced our understanding of the biology, phenotype, genotype, and therapy of medulloblastoma. Further efforts to integrate laboratory and clinical studies of this tumor may allow design of novel therapeutic approaches resulting in enhanced disease-free survival.

Key words

medulloblastoma c-myc neuronal glial chemotherapy radiotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rorke LB: The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 42: 1–15, 1983Google Scholar
  2. 2.
    Rubinstein LJ: Embryonal central neurcepithelial tumors and their differentiating potential. A cytogenetic view of a complex neuro-oncological problem. J Neurosurg 62: 795–805, 1985Google Scholar
  3. 3.
    Bailey P, Cushing H: Medulloblastoma cerebelli: A common type of midcerebellar glioma of childhood. Arch Neurol Psychiatr (Chicago) 14: 192–224, 1925Google Scholar
  4. 4.
    Bailey OT: Genesis of the Percival Bailey-Cushing classification of gliomas. Pediatr Neurosci 12: 261–265, 1985–86Google Scholar
  5. 5.
    Globus JH, Strauss I: Spongioblastoma multiforme. A primary malignant form of neoplasm: Its clinical and anatomic features. Arch Neurol Psychiat (Chicago) 14: 139–191, 1925Google Scholar
  6. 6.
    Schaper A: Die fruhesten differenzirungsuorgange in central nerven system; kirtische studie und versuch encr geschichte der entwickelung nerwser substanz. Arch F Entwicklingsmechn d' Organ, Leipz 5: 81–132, 1897Google Scholar
  7. 7.
    Rubenstein LJ: The cerebellar medulloblastoma: Its origin, differentiation, morphological variants and biological behavior. In: Vincken PJ, Bruyn GW (eds) Tumors of the Brain and Skull, Part III. Elsevier, New York, Chapter 9, pp 167–194, 1977Google Scholar
  8. 8.
    Bailey P, Cushing H: A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis. Lippencott, Philadelphia, 1926Google Scholar
  9. 9.
    Burger PC, Grahmann FC, Bliestle A, Kleihues P: Differentiation in the medulloblastoma. A histological and immunohistochemical study. Acta Neuropathol (Berl) 73: 115–123, 1987Google Scholar
  10. 10.
    Coffin CM, Mukai K, Delmer LP: Glial differentiation in medulloblastomas. Am J Surg Pathol 7: 555–565, 1983Google Scholar
  11. 11.
    Palmer JO, Kasselberg AG, Netsky MG: Differentiation of medulloblastoma. Studies including immunohistochemical localization of glial fibrillary acidic protein. J Neurosurg 55: 161–169, 1981Google Scholar
  12. 12.
    McAllister RM, Isaacs H, Rongey R, Peer M, Au W, Soukup SW, Gardner MB: Establishment of a human medulloblastoma cell line. Int J Cancer 20: 206–212, 1977Google Scholar
  13. 13.
    Stratton MR, Darling J, Pilkington GJ, Lantos PL, Reeves BR, Cooper CS: Characterization of the human cell line TE671. Carcinogenesis 10: 899–905, 1989Google Scholar
  14. 14.
    Jacobsen PF, Jenkyn DJ, Papadimitriou JM: Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 44: 472–485, 1985Google Scholar
  15. 15.
    Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Wikstrand CJ, Halperin EC, Bigner DD: Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol 44: 592–605, 1985Google Scholar
  16. 16.
    Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, He X, Wikstrand CJ, Kurtzberg J, Berens ME, Halperin EC, Bigner DD: Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol 130: 472–484, 1988Google Scholar
  17. 17.
    Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD: Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 50: 2347–2350, 1990Google Scholar
  18. 18.
    Tamura K, Shimizu K, Yamada M, Okamoto Y, Matsui Y, Park KC, Mabuchi E, Moriuchi S, Mogami H: Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation. Cancer Res 49: 5380–5384, 1989Google Scholar
  19. 19.
    He X: Phenotypic analysis of human medulloblastoma and distribution of the gangliosides GD3 and GD2 in human neuroectodermal tumors. Duke University, Ph.D. Thesis, 197 pp, 1990Google Scholar
  20. 20.
    He X, Skapek SX, Wikstrand CJ, Friedman HS, Trojanowski JQ, Kemshead JT, Coakham HB, Bigner SH, Bigner DD: Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropath Exp Neurol 48: 48–68, 1989Google Scholar
  21. 21.
    Gould VE, Jansson DS, Molenaar WM, Rorke LB, Trojanowski JQ, Lee VMY, Packer RJ, Franke WW: Primitive neuroectodermal tumors of the central nervous system. Patterns of expression of neuroendocrine markers, and all classes of intermediate filament proteins. Lab Invest 62: 498–509, 1990Google Scholar
  22. 22.
    Svennerholm L: Immunological and tumoral aspects of gangliosides. In: Ledeen RW, Hogan G, Tettamanti G, Yates AJ, Yu RK (eds) New Trends in Ganglioside Research. Fidia Research Series, Liviana Press, Padua, pp 135–150, 1988Google Scholar
  23. 23.
    Mansson JE, Fredman P, Bigner DD, Molin K, Rosengren B, Friedman HS, Svennerholm L: Characterization of new gangliosides of the lactotetraose series in murine xenografts in a human Gloma cell line. FEBS Lett 201: 109–113, 1986Google Scholar
  24. 24.
    Fuchs HE, Archer GE, Colvin OM, Bigner SH, Schuster JM, Fuller GN, Schold Jr SC, Muhlbaier LH, Friedman HS, Bigner DD: Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 50: 1954–1959, 1990Google Scholar
  25. 25.
    Kadin ME, Rubinstein LJ, Nelson JS: Neonatal cerebellar medulloblastoma originating from the fetal external granular layer. J Neuropathol Exp Neurol 29: 583–600, 1970Google Scholar
  26. 26.
    Raaf J, Kernohan JW: Relation of abnormal collections of cells in posterior medullary velum of cerebellum to origin of medulloblastoma. Arch Neurol Psychiatr 52: 163–169, 1944Google Scholar
  27. 27.
    Zimmerman, HM: Brain tumors: Their incidence and classification in man and their experimental production. Ann NY Scad Sci 159: 337–359, 1969Google Scholar
  28. 28.
    Zu Rhein GM, Varakis JN: Perinatal induction of medulloblastomas in Syrian golden hamsters by a human polyoma virus (JC). Natl Cancer Inst Monogr 51: 205–208, 1979Google Scholar
  29. 29.
    General discussion of Part One. In: Primary Brain Tumors: A Review of Histologic Classification. Fields WS (ed) Springer Verlag, New York, pp 91–113, 1989Google Scholar
  30. 30.
    Foon KA, Gale RP, Todd III RF: Recent advances in the immunologic classification of leukemia. Semin Hematol 23: 257–283, 1986Google Scholar
  31. 31.
    Bigner DD: Phenotypic analysis of medulloblastoma with monoclonal antibodies. In: Primary Brain Tumors: A Review of Histologic Classification. Fields WS (ed) Springer-Verlag, New York, pp 70–78, 1989Google Scholar
  32. 32.
    Cox D, Yuncken C, Spriggs AI: Minute chromatin bodies in malignant tumours of childhood. Lancet ii: 55–58, 1965Google Scholar
  33. 33.
    Cox D: Chromosome studies in 12 solid tumours from children. Br J Cancer 22: 402–414, 1968Google Scholar
  34. 34.
    Mark J: Chromosomal characteristics of neurogenic tumors in children. Acta Cytol 14: 510–518, 1970Google Scholar
  35. 35.
    Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD: Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 30: 91–101, 1988Google Scholar
  36. 36.
    Griffin CA, Hawkins AL, Packer RJ, Rorke LB, Emanuel BS: Chromosome abnormalities in pediatric brain tumors. Cancer Res 48: 175–180, 1988Google Scholar
  37. 37.
    Bigner SH, Mark J, Bullard DE, Mahaley MS, Bigner DD: Patterns of the early, gross chromosomal changes in malignant human gliomas. Hereditas 101: 103–113, 1984Google Scholar
  38. 38.
    Bigner SH, Mark J, Bullard DE, Mahaley Jr MS, Bigner DD: Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations. Cancer Genet Cytogenet 22: 121–135, 1986Google Scholar
  39. 39.
    Rouah E, Wilson DR, Armstrong DL, Darlington GJ: N-myc amplification and neuronal differentiation in human primitive neuroectodermal tumors of the central nervous system. Cancer Res 49: 1797–1801, 1989Google Scholar
  40. 40.
    James CD, He J, Carlbom E, Mikkelsen T, Ridderheim P-A, Cavenee WK, Collins VP: Loss of genetic information in central nervous system tumors common to children and young adults. Genes, Chromosomes and Cancer 2: 94–102, 1990Google Scholar
  41. 41.
    Wasson JC, Saylors III RL, Zeltzer P, Friedman HS, Bigner SH, Burger PC, Bigner DD, Look AT, Douglass EC, Brodeur GM: Oncogene amplification in pediatric brain tumors. Cancer Res. 50: 2987–2990, 1990Google Scholar
  42. 42.
    Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124, 1984Google Scholar
  43. 43.
    Cushing H: Experiences with the cerebellar medulloblastomas. A critical review. Acta Pathol Microbiol Scand 7: 1–86, 1930Google Scholar
  44. 44.
    Rippe DJ, Boyko OB, Friedman HS, Oakes WJ, Schold Jr SC, DeLong GR, Meisler WJ: GD-DTPA-enhanced MR imaging of leptomeningeal spread of primary intracranial CNS tumor in children. Am J Neuroradiol 11: 329–332, 1990Google Scholar
  45. 45.
    Jenkin D, Goddard K, Armstrong D, Becker L, Berry M, Chan H, Doherty M, Greenberg M, Hendrick B, Hoffman H, Humphreys R, Sonley M, Weitzman S, Zipursky A: Posterior fossa medulloblastoma in childhood: Treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 19: 265–274, 1990Google Scholar
  46. 46.
    Norris DG, Bruce DA, Byrd RL, Schut L, Littman P, Bilaniuk LT, Zimmerman RA, Capp R: Improved relapse-free survival in medulloblastoma utilizing modern techniques. Neurosurgery 9: 661–664, 1981Google Scholar
  47. 47.
    Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE: Medulloblastoma: Clinical presentation and management. Experience at the Hospital for Sick Children, Toronto, 1950–1980. J Neurosurg 58: 543–552, 1983Google Scholar
  48. 48.
    Allen JC, Bloom J, Ertel I, Evans A, Hammond D, Jones H, Levin V, Jenkin D, Sposto R, Wara W: Brain tumors in children: Current cooperative and institutional chemotherapy trials in newly diagnosed recurrent disease. Semin Oncol 13:110–122, 1986Google Scholar
  49. 49.
    Packer RJ, Sutton LN, D'Angio G, Evans AE, Schut L: Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediatr Neurosci 12: 272–282, 1985–86Google Scholar
  50. 50.
    Tait DM, Thornton-Jones H, Bloom HJG, Lemerle J, Morris-Jones P: Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP). Eur J Cancer 26: 464–469, 1990Google Scholar
  51. 51.
    Chang CH, Housepian EM, Herbert Jr C: An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93: 1351–1359, 1969Google Scholar
  52. 52.
    Harisiadis L, Chang CH: Medulloblastoma in children: A correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 2: 833–841, 1977Google Scholar
  53. 53.
    Berry MP, Jenkin RD, Keen CW, Nair BD, Simpson WJ: Radiation treatment for medulloblastoma. A 21-year review. J Neurosurg 55: 43–51, 1981Google Scholar
  54. 54.
    Deutsch M, Scotti LN, Hardman DR, Reigel DH, Scarff TB: Myelography in patients with medulloblastoma. Radiology 117: 467–468, 1975Google Scholar
  55. 55.
    Deutsch M, Reigel DH: Myelography and cytology in the treatment of medulloblastoma. Int J Radiat Oncol Phys 7: 721–725, 1981Google Scholar
  56. 56.
    Deutsch M: Myelography and cytology for staging very young children with medulloblastoma. Am J Clin Oncol (CCT) 6: 657–660, 1983Google Scholar
  57. 57.
    Deutsch M: Medulloblastoma: Staging and treatment outcome. Int J Radiat Oncol Biol Phys 14: 1103–1107, 1988Google Scholar
  58. 58.
    Wiener MD, Boyko OB, Friedman HS, Hockenberger B, Oakes WJ: False-positive spinal MRI findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. Am J Neuroradiol 11: 1100–1103, 1990Google Scholar
  59. 59.
    Kopelson G, Linggood RM, Kleinman GM: Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management. Cancer 51: 312–319, 1983Google Scholar
  60. 60.
    Packer RJ, Sutton LN, Rorke LB, Littman PA, Sposto R, Rosenstock JG, Bruce DA, Schut L: Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 61: 296–301, 1984Google Scholar
  61. 61.
    Caputy AJ, McCullough DC, Manz HJ, Pateerson K, Hammock MK: A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 66: 80–87, 1987Google Scholar
  62. 62.
    Taomoto K, Tomita T, Raimondi AJ, Leestma JE: Medulloblastomas in childhood: Histological factors influencing patients' outcome. Childs Nerv Syst 3: 354–360, 1987Google Scholar
  63. 63.
    Yasue M, Tomita T, Engelhard H, Gonzalez-Crussi F, McLone DG, Bauer KD: Prognostic importance of DNA ploidy in medulloblastoma of childhood. J Neurosurg 70: 385–391, 1989Google Scholar
  64. 64.
    Allen JC, Epstein F: Medulloblastoma and other primary malignant neuroectodermal tumors of the CNS. The effect of patients' age and extent of disease on prognosis. J Neurosurg 57: 446–451, 1982Google Scholar
  65. 65.
    Paterson E, Farr RF: Cerebellar medulloblastoma: Treatment by irradiation of the whole central nervous system. Acta Radiol 39: 323–336, 1953Google Scholar
  66. 66.
    Jenkin RDT: Medulloblastoma in childhood: Radiation therapy. Can Med Assoc J (Ottawa) 100: 51–53, 1969Google Scholar
  67. 67.
    Brunat-Mentigny M, Bernard JL, Tron P, Bacheolt C, Carton M, Philip T, Dutou L, Alphonsi SM, Raybaud C, Lapras C: Treatment of medulloblastomas with surgery-chemotherapy and radiation therapy limited to the posterior fossa and the spinal cord. International Society of Pediatric Oncology (SIOP) XVIII Annual Meeting, Yugoslavia, 1986Google Scholar
  68. 68.
    Hughes EN, Shillito J, Sallan SE, Loeffler JS, Cassady JR, Tarbell NJ: Medulloblastoma at the Joint Center for Radiation Therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 61: 1992–1998, 1988Google Scholar
  69. 69.
    Silverman CL, Simpson JR: Cerebellar medulloblastoma: The importance of posterior fossa dose to survival and patterns of failure. Int J Radiat Oncol Biol Phys 8: 1869–1876, 1982Google Scholar
  70. 70.
    Tomita T, McClone DG: Medulloblastoma in childhood: Results of radical resection and low-dose neuraxis radiation therapy. J Neurosurg 64: 238–242, 1986Google Scholar
  71. 71.
    Friedman HS, Oakes WJ: The chemotherapy of posterior fossa tumors in childhood. J Neurooncol 5: 217–229, 1987Google Scholar
  72. 72.
    Evans AE, Jenkin RDT, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, Hammond GD: The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone. J Neurosurg 72: 572–582, 1990Google Scholar
  73. 73.
    McIntosh S, Chen M, Sartain PA, Duncan C, Fishburn R, Klatskin EH, Schwartz AD, Venes JL: Adjuvant chemotherapy for medulloblastoma. Cancer 56: 1316–1319, 1985Google Scholar
  74. 74.
    Packer RJ, Siegel KR, Sutton LN, Evans AE, D'Angio G, Rorke LB, Bunin GR, Schut L: Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: A preliminary report. Ann Neurol 24: 503–508, 1988Google Scholar
  75. 75.
    Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold Jr SC, Jacobsen PF, Muhlbaier LH, Bigner DD: Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189–4195, 1988Google Scholar
  76. 76.
    Allen JC, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55: 749–756, 1981Google Scholar
  77. 77.
    Friedman HS, Mahaley Jr MS, Schold Jr SC, Vick NA, Falletta JM, Bullard DE, D'Souza BJ, Khandekar JD, Lew S, Oakes WJ, Bigner DD: Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurg 18: 335–340, 1986Google Scholar
  78. 78.
    Friedman HS, Schold Jr SC, Mahaley Jr MS, Colvin OM, Oakes WJ, Vick NA, Burger PC, Bigner SH, Borowitz M, Halperin EC, Djang W, Falletta JM, DeLong R, Garvin JH, DeVivo DC, Norris D, Golembe B, Winter J, Bodziner RA, Sipahi H, Bigner DD: Phase II treatment of medulloblastoma and pineoblastoma with melphalan: Clinical therapy based on experimental models of human medulloblastoma. J Clin Oncol 7: 904–911, 1989Google Scholar
  79. 79.
    Schold SC Jr, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, Swenberg JA, Kleihues P: O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 70: 573–577, 1989Google Scholar
  80. 80.
    Duffner PK, Cohen ME, Horowitz M, Friedman HS, Kun LE, Mahoney DH, Das L, Holbrook CT: Postoperative chemotherapy and delayed irradiation in children less than 36 months of age with malignant brain tumors (Abstract) Ann Neurol 20: 424, 1986Google Scholar
  81. 81.
    Horowitz ME, Kun LE, Mulhern RK, Kovnar EH, Sanford RA, Hockenberger BM, Greeson FL, Langston JW, Fairclough DL, Jenkins III JJ: Feasibility and efficacy of preirradiation chemotherapy for pediatric brain tumors. Neurosurgery 22: 687–690, 1988aGoogle Scholar
  82. 82.
    Horowitz ME, Mulhern RK, Kun LE, Kovnar E, Sanford RA, Simmons J, Hayes FA, Jenkins III JJ: Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer 61: 428–434, 1988bGoogle Scholar
  83. 83.
    Baram TZ, van Eys J, Dowell RE, Cangir A, Pack B, Bruner JM: Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy. Cancer 60: 173–177, 1987Google Scholar
  84. 84.
    Raimondi AJ, Tomita T: Medulloblastoma in childhood. Comparative results of partial and total resection. Childs Brain 5: 310–328, 1979Google Scholar
  85. 85.
    Hirsh JF, Renier D, Czernichow P, Benveniste L, PierreKahn A: Medulloblastoma in childhood. Survival and functional results. Acta Neurochir 48: 1–15, 1979Google Scholar
  86. 86.
    Packer RJ, Sposto R, Atkins TE, Sutton LN, Bruce DA, Siegel KR, Rorke LB, Littman PA, Schut L: Quality of life in children with primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Pediat Neurosci 13: 169–175, 1987Google Scholar
  87. 87.
    Venes J: Comments on article by Packer et al. Pediatr Neurosci 13: 175, 1987Google Scholar
  88. 88.
    Oberfield SE, Allen JC, Pollack J, New MI, Levine LS: Long-term endocrine sequelae after treatment of medulloblastoma: Prospective study of growth and thyroid function. J Pediatr 108: 219–223, 1986Google Scholar
  89. 89.
    Probert JC, Parker BR, Kaplan HS: Growth retardation in children after megavoltage irradiation of the spine. Cancer 32: 634–639, 1973Google Scholar
  90. 90.
    Roggli VL, Estrada R, Fechner RE: Thyroid neoplasia following irradiation for medulloblastoma: Report of two cases. Cancer 43: 2232–2238, 1979Google Scholar
  91. 91.
    Schmibauer M, Budka H, Buckner B, Vorkapic P: Glioblastoma developing at the site of a cerebellar medulloblastoma treated 6 years earlier. J Neurosurg 67: 915–918, 1987Google Scholar
  92. 92.
    Lashford LS, Davies AG, Richardson RB, Bourne SP, Bullimore JA, Eckert H, Kemshead JT, Coakham HB: A pilot study of 131–1 monoclonal antibody in cases of neoplastic meningitis. Cancer 61: 857–868, 1988Google Scholar
  93. 93.
    Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, Slack N, Bullimore J, Pizer B, Papanastassiou V, Kemshead JT, Coakham HB, Lashford LS: Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 62: 637–642, 1990Google Scholar
  94. 94.
    Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold Jr SC, Hilton J, Bigner DD: Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. JNCI 81: 524–527, 1989Google Scholar
  95. 95.
    Lipptiz BE, Halperin EC, Griffith OW, Colvin OM, Honore G, Ostertag CB, Bigner DD, Friedman HS: L-Buthioninesulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. Neurosurgery 26: 255–260, 1990Google Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Henry S. Friedman
    • 1
    • 3
  • W. fnJerry Oakes
    • 1
    • 2
  • Sandra H. Bigner
    • 3
  • Carol J. Wikstrand
    • 3
  • Darell D. Bigner
    • 3
    • 4
  1. 1.Departments of PediatricsDuke University Medical CenterDurhamUSA
  2. 2.SurgeryDuke University Medical CenterDurhamUSA
  3. 3.Pathology Preuss Laboratory for Brain Tumor ResearchDuke University Medical CenterDurhamUSA
  4. 4.Preuss Laboratory for Brain Tumor ResearchDuke University Medical CenterDurhamUSA
  5. 5.Department of PediatricsDuke University Medical CenterDurhamUSA

Personalised recommendations